<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893618</url>
  </required_header>
  <id_info>
    <org_study_id>PK024</org_study_id>
    <nct_id>NCT02893618</nct_id>
  </id_info>
  <brief_title>A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)</brief_title>
  <official_title>A 5 Treatment Period Crossover Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essentialis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Essentialis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR,
      1 of which is administered both with and without food.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR,
      1 of which is administered both with and without food, with a 10 Day washout period between
      treatments. There will be 8 treatment sequences with 4 subjects randomized to each.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters: Cmax</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Cmax derived from PK samples taken at 0, 1, 3, 6, 9, 12, 15, 18, 21 and 24 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters: AUC0-24</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>AUC0-24 derived from PK samples taken at 0, 1, 3, 6, 9, 12, 15, 18, 21 and 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: CL/F</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>CL/F derived from PK samples taken at 0, 1, 3, 6, 9, 12, 15, 18, 21 and 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Tmax</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Tmax derived from PK samples taken at 0, 1, 3, 6, 9, 12, 15, 18, 21 and 24 hours</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>DCCR 75 mg fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCCR 150 mg fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCCR 300 mg fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCCR 450 mg fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCCR 300 mg fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered a single 300 mg dose of DCCR after a standardized meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide choline controlled-release tablet</intervention_name>
    <description>QD tablet formulation of choline salt of diazoxide</description>
    <arm_group_label>DCCR 75 mg fasted</arm_group_label>
    <arm_group_label>DCCR 150 mg fasted</arm_group_label>
    <arm_group_label>DCCR 300 mg fasted</arm_group_label>
    <arm_group_label>DCCR 450 mg fasted</arm_group_label>
    <arm_group_label>DCCR 300 mg fed</arm_group_label>
    <other_name>DCCR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to follow verbal and written instructions

          -  Informed consent form signed by the subject

          -  Completed screening within 7 days prior to dosing

          -  BMI between 18.5 and 35 kg/m2

          -  Generally healthy

          -  fasting glucose less than or equal to 100 mg/dL

          -  HbA1c less than or equal to 6%

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  absence of contraception

          -  administration of investigational drug within 1 month prior to screening

          -  anticipated requirement for prohibited medication (systemic corticosteroids or
             anti-diabetic medications)

          -  allergic reaction to or significant intolerance of diazoxide, thiazides or
             sulfonamides

          -  known type 1 or type 2 diabetes mellitus

          -  congestive heart failure

          -  gastric bypass surgery

          -  history of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 7, 2016</last_update_submitted>
  <last_update_submitted_qc>September 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

